ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments

UnknownOBSERVATIONAL
Enrollment

123

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

February 1, 2020

Study Completion Date

December 31, 2021

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Hormonal therapy-based treatments

Hormonal therapy-based treatments, ex. HT single agent, HT plus other targeted therapy, HT plus everolimus, HT plus metronomic oral chemotherapy or oral chemotherapy only

Trial Locations (2)

100

National Taiwan University Hospital, Taipei

114

Tri-Service General Hospital, Taipei

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

National Taiwan University Hospital

OTHER